88.Issue 11 november 25 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 12, Issue : 11, November – 2025

Title:

FORMULATION AND IN-VITRO EVALUATION OF DALFAMPRIDINE SUSTAINED RELEASE TABLETS USING VARIOUS POLYMERS

Authors :

Suresh.G, Chandrasekhara Rao Baru, Nandini nagula, Sushma Desai

Abstract :

In present investigation the sustained release tablets of Dalfampridine was formulated to study effect of various natural polymers using Tragacanth, Acacia gum and Xanthan gum. The model is based on a novel dosage form designed to deliver a drug into the gastrointestinal tract in a controlled manner. Matrix tablets were prepared by direct compression method. As a pre- requisite and part of pre-formulation studies, drug along with selected excipients and as optimized formulation was subjected to FT-IR studies. It was found that no interaction among excipients occurred, as no extra peaks obtained. Tablets were evaluated for various IPQC tests like hardness, friability, content uniformity and in-vitro drug release by USP paddle apparatus. It was found that the release of drug D3 formulation showed 99.83% the formulation gave better release amongst formulations, showing highest release following Peppas release kinetics.
Key words: Dalfampridine, Tragacanth, Acacia gum, Xanthan gum, direct compression and Sustained release matrix tablets.

Cite This Article:

Please cite this article in press Sushma Desai et al., Formulation And In-Vitro Evaluation Of Dalfampridine Sustained Release Tablets Using Various Polymers, Indo Am. J. P. Sci, 2025; 12(11).

REFERENCES:

1.Altaf AS, Friend DR, MASRx and COSRx. Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003; 1: 102-117.
2.Reddy KR., Mutalik S, Reddy S. AAPS Pharm. Sci. Tech.2003; 4: 19. 121-125.
3.Mohammed AD et al. Release of propranolol hydrochloride from matrix tablets containing sodium carboxymethylcellulose and Hydroxypropyl methyl cellulose. Pharm Dev Tech.1999; 4: 313-324.
4.Salsa T, Veiga F. Drug Develop. Ind Pharm. 1997; 23: 931.
5.Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) Modern Pharmaceutics, 3rd Ed, Revised and Expanded, Drugs and the Pharmaceutical Sciences., Marcell Dekker, Inc. New York. 1995; 72: 575- 609.
6.Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery systems Modern Pharmaceutics, 4thed; 2003; 121: 501-502.
7.Lee BJ, Ryu SG, Cui JH, Drug Dev. Ind.Pharm.1999; 25: 493-501.
8.Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Ed. Modern Pharmaceutics, 3rdEd Marcel Dekker Inc. New York. 1996; 72: 575.
9.Vidyadhara S, Rao PR, Prasad JA. Indian J Pharm Sci. 2004; 66: 188-192.
10.Bogner RH. Bioavailability and bioequivalence of extended-release oral dosage forms. US Pharmacist. 1997; 22: 3–12.
11.Rogers JD, Kwan KC. Pharmacokinetic requirements for controlled-release dosage forms. In: John Urquhart, ed. Controlled-release Pharmaceuticals. Academy of Pharmaceutical Sciences. American Pharmaceutical Association. 1979: 95–119.
12.Madan PL. Sustained-release drug delivery systems, part II: Preformulation considerations. Pharm Manu fact. 1985; 2: 41–45.
13.Wani MS, Controlled Release System-A Review, 2008; 6 1: 56-62.
14.Banker GS, Anderson NR. The Theory and Practice of Industrial Pharmacy: Tablet, Lachman, (3rded) Varghese Publishing House, Bombay. 1990; 3: 293-303.
15. Lee VHL, Controlled Drug Delivery Fundamentals and Applications: Influence of drug properties on design, Marcel Dekker, INC, and New York. 1987; 2: 16-29.
16.Manish R, Jayesh P, Siahboomi AR. Hydrophilic Matrices for Oral Extended Release: Influence of Fillers on Drug Release from HPMC Matrices. Pharma Times. 2010; 42(04): 67-73.
17.Kumar KP et al. Innovations in Sustained Release Drug Delivery System and Its Market Opportunities. J Chem Pharm Res. 2010; 2 1: 349-360.
18.Brahmankar DM, Sunil B. Jaishwal. “Controlled release medication” chapter 15th in “Bio pharmaceutics and Pharmacokinetics – A Treatise, 1st ed, 2010; 1: 347- 353.
19.Stanley S. Davis, Formulation strategies for abs windows. Drug Discovery Today, 2005; 10: 249-257.
20.Modi SA et al. Sustained Release Drug Delivery System: A Review. Int J Pharma. Res Dev. 2011; 2 (12): 147-160.
21.Lieberman HA, Lachman L, Schwartz JB., Pharmaceutical Dosage Forms: Tablets, 2011; 3 (2): 199-287.
22.Aulton ME. Pharmaceutics: The Science of Dosage Form Design. 2005; 2: 296-298.
23.Wise DL. Handbook of Pharmaceutical Controlled Release Technology. Inc. 2005; 2: 5-24.
24.Jantzen GM, Robinson JR. Sustained and Controlled- Release Drug Delivery systems Modern Pharmaceutics, 4thed; 2011; 121: 501-502.
25.Sonal Sahu, Rohit Dangi, Rohit Patidar, Rukhsaar, Jagdish Rathi, Vivek Asati. Formulation and evaluation of sustain released matrix tablet of atenolol. Journal of Drug Delivery & Therapeutics. 2019; 9(1):183-189.
26.Kar Ayan Kumar, Majumder Tandrima, Majumdar Subhabrota, Mahanti Beduin, Kar Banhishikha1, Chakraborty Satyam, Parya Hiranmoy, Saha Surajit. Design, formulation and evaluation of sustained release bilayer tablets of ciprofloxacin hydrochloride. Journal of Drug Delivery & Therapeutics. 2019; 9(1):46-53.
27.M. Sunitha Reddy and S. Archana. Formulation And Evaluation Of Sustained Release Tablets Of Repaglinide Using Hydrophilic Natural And Synthetic Polymers. IJPSR, 2018; Vol. 9(7): 2914-2920.